Related Experiment Video
Updated: Jun 5, 2025
A High-throughput Shigella-specific Bactericidal Assay
Published on: February 27, 2019
Development and Characterization of a 13-Plex Binding Assay to Detect Shigella Antibodies in Human Samples
Insights
A new Luminex-based method can measure antibodies against 13 Shigella antigens in human serum. This tool supports the development of multivalent vaccines against Shigella, a leading cause of childhood diarrhea.
Area of Science:
- Microbiology
- Immunology
- Vaccinology
Background:
- * Shigella is a primary bacterial cause of global diarrhea, particularly in children under 5.
- * Rising antibiotic resistance in Shigella necessitates vaccine development.
- * Current vaccine development faces challenges in covering prevalent Shigella serotypes with a multivalent approach.
Purpose of the Study:
- * To establish a reproducible Luminex-based assay for measuring antibodies against 13 Shigella antigens.
- * To facilitate large-scale data collection for Shigella vaccine development.
Main Methods:
- * Development and validation of a Luminex-based multiplex immunoassay.
- * Measurement of specific antibodies in human serum samples against 13 Shigella antigens.
Main Results:
- * A reliable method for quantifying antibodies to 13 Shigella antigens was established.
- * The assay demonstrated reproducibility for analyzing serum samples.
Conclusions:
- * The developed Luminex assay is a valuable tool for Shigella vaccine research.
- * This method will accelerate data collection from vaccinated or exposed individuals, aiding multivalent vaccine design.
Abstract:
Shigella is the leading bacterial cause of diarrhea worldwide, with increasing levels of antibiotic resistance. The greatest burden is among children aged <5 years in low- and middle-income countries, and efforts are ongoing to develop vaccines against this pathogen. One of the challenges associated with the development of a vaccine against Shigella is the need for a multivalent vaccine covering the most prevalent Shigella serotypes. Epidemiologic studies to better understand the prevalence of the Shigella serotypes and inform vaccination schedules are very useful, with clinical data showing the ability of vaccines to elicit cross-reactive antibodies. Here, we set up a Luminex-based method able to reproducibly measure antibodies specific to 13 Shigella antigens in human sera. This method will allow the rapid collection of large amounts of data based on the analysis of serum samples from vaccinated individuals or people naturally exposed to Shigella, supporting the development of a vaccine against this disease.
